- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07939516
Individualized Genotype-guided Antiplatelet Therapy in Patients With Acute Coronary Syndrome (IGNITION)
Rationale Patients diagnosed with acute coronary syndrome (ACS), a sudden medical emergency where blood flow to the heart is blocked, require dual antiplatelet therapy (DAPT) for 12 months to prevent dangerous blood clots to form. This typically includes the combination of aspirin and a form of P2Y12 inhibitor, a specific type of medicine that stops platelet cells to clot. Irrespective of the treatment strategy (i.e., invasive through angioplasty or conservative with medication only), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events.
Although ischemic complications (problems that happen when the heart doesn't get enough blood and oxygen) usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. However, in 30% of the (white) European patients, there is a small change (mutation) in their genetic material. They are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate processing of clopidogrel in to its active form.
Despite knowledge of these loss of function mutations, current treatment guidelines for ACS do not provide specific recommendations on individualized, genotype-based treatment (i.e. using the unique genetic code to choose the medicine that works best) with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as they were too small and cautious to give definite answers.
Objective The goal of this clinical trial is to investigate whether individualized genotype-guided treatment with DAPT after ACS diagnosis is just as safe and effective as standard clinical practice.
Participants will receive:
- Standard treatment at the discretion of the cardiologist, or
- Genotype-guided treatment (based on the presence of a LOF allele)
Participants included in the genotype-guided group who do not carry a LOF allele will be classified as normal processors of clopidogrel, and will de-escalate after 30 days from standard therapy to clopidogrel. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place and treatment will continue as previously started.
Participants will be followed for 18 months after ACS diagnosis to collect medical data and to complete questionnaires.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale Patients diagnosed with acute coronary syndrome (ACS) require dual antiplatelet therapy (DAPT) for 12 months. This typically includes aspirin and a P2Y12 inhibitor. Irrespective of the treatment strategy (i.e., invasive or conservative), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events.
Although ischemic complications usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. Yet, in 30% of the (white) European patients are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate metabolization of clopidogrel.
Despite knowledge of these loss of function mutations, current ACS guidelines do not provide specific recommendations on individualized, genotype-based treatment with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as the conucted trials were underpowered due to sample size calculations based on ischemic endpoints, and the exclusion of ACS patients with high-risk features.
Objective
This randomized clinical trial aims to investigate whether individualized genotype-guided DAPT is non-inferior at 18 months follow-up to standard clinical practice of DAPT in all-comer patients with ACS with regard to:
- the primary endpoint of Ischemic Endpoint, a composite of cardiovascular death, myocardial infarction, or ischemic stroke, and
- the co-primary endpoint of Net Adverse Cardiovascular Events (NACE), a composite of major bleeding, cardiovascular death, myocardial infarction, or any stroke.
Trial design This is a randomized, investigator-initiated, multicentre trial with 1:1 randomization of all-comer ACS patients for genotype-guided antiplatelet therapy, stratified for the presence of diabetes mellitus, sex and PCI.
Trial population All patients of 18 years or older with ACS, irrespective of the treatment strategy. If patients did not undergo a coronary angiography, there must be a history of coronary artery disease, proven myocardial defect by cardiac imaging that matches with previous MI, proven myocardial ischemia, or a known coronary obstruction ≥30% as previously visualized.
Interventions
If no major events (defined by NACE) occur during the first 30 days, patients will be randomly assigned (1:1) to:
- Standard treatment at the discretion of the cardiologist, or
- Genotype-guided treatment (based on CYP2C19 loss of function alleles) Patients included in the genotype-guided group who do not carry a LOF allele will be classified as normal or ultrafast metabolizers, and will de-escalate after 30 days from standard therapy (with ticagrelor or prasugrel) to clopidogrel. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place and treatment will continue as previously started. If the test results are inconclusive, de-escalation will be carried out.
Ethical considerations As both treatment strategies (i.e. aspirin plus clopidogrel or ticagrelor or prasugrel) are commonly used in treatment of ACS and considered standard care in Europe according to the ESC guidelines, no risks will be attached to treatment with any of the P2Y12 inhibitors. Patients who receive an individualized treatment strategy will possibly benefit from this, due to lower risk of bleeding complications.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Eline Ploumen, MD, PhD
- Phone Number: +31(0)53 487 2105
- Email: e.ploumen@mst.nl
Study Locations
-
-
Overijssel
-
Almelo, Overijssel, Netherlands, 7609 PP
- Ziekenhuis Groep Twente
-
Contact:
- Joost Kruik, MD
- Phone Number: +31(0)88 708 33 00
- Email: j.kruik@zgt.nl
-
Enschede, Overijssel, Netherlands, 7512 KZ
- Medisch Spectrum Twente
-
Contact:
- Eline Ploumen, MD, PhD
- Phone Number: +31(0)53 487 2105
- Email: e.ploumen@mst.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Patients of 18 years and older, who are capable of providing informed consent and were diag-nosed with an acute coronary syndrome
-
Patients with a coronary angiography showing obstructive coronary artery disease at time of di-agnosis (or up to 30 days thereafter)
-
Patients in whom no coronary angiography is performed during the index hospitalization or the first 30 days after the ACS, need to have at least one of the following:
- known history of coronary artery disease (i.e., a previous MI, PCI, or coronary artery bypass grafting (CABG)),
- proven myocardial defect by cardiac imaging that matches with previous MI,
- proven myocardial ischemia, or
- known coronary artery atherosclerosis as previously visualized.
Exclusion Criteria:
- Known intolerance to or absolute contraindication for clopidogrel, ticagrelor, prasugrel or acetyl-salicylic acid.
- Use of oral anticoagulant therapy.
- Contra-indication for standard treatment with ticagrelor.
- Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or lap-aroscopic) within the past 6 months prior to randomization or any major surgical procedure planned 6 months after randomization.
- Participation in another randomized cardiovascular device trial or randomized pharmacological trial related to antithrombotic and/or anticoagulant therapy before reaching the primary end-point.
- Known pregnancy, adherence to scheduled follow-up is unlikely, or life expectancy is assumed to be less than 18 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard therapy
Dual antiplatelet therapy described at the cardiologist's discretion |
Patients randomized for the standard therapy arm will receive dual antiplatelet therapy at the descretion of the cardiologist |
|
Experimental: Genotype based therapy
Dual antiplatelet therapy based on CYP2C19 genotype. In case of normal or ultrafast metabolizer, patient will receive Clopidogrel 30-days after acute coronary syndrome. In case of proven carrier of the loss-of-function allele, patient will continue with ticagrelor. |
All patients with ACS can be enrolled. Randomization will take place at time of ACS diagnosis. For the first 30 days after the index event, patients will be treated with DAPT as prescribed by the cardiologist. Patients who experience a major event (any death, spontaneous MI, definite stent thrombosis, any stroke, and major bleeding) during the first 30 days will be excluded from the main analysis. For these patients, DAPT treatment will remain unchanged. Included patients will be randomly assigned (1:1) to:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ischemic endpoint
Time Frame: At 18 months follow-up
|
Composition of cardiovascular death, myocardial infarction, definite stent thrombosis and ischemic stroke |
At 18 months follow-up
|
|
Net Adverse Cardiovascular Events
Time Frame: At 18 months follow-up
|
Composition of cardiovascular death, major bleeding, myocardial infarction, definite or probable stent thrombosis, and any stroke |
At 18 months follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events
Time Frame: At 18 months follow-up
|
Death, Myocardial infarction, repeat revascularization, stroke, stent thrombosis, and bleeding |
At 18 months follow-up
|
|
Patient reported chest pain
Time Frame: At 12- and 18-months follow-up
|
Severity of chest pain by the Canadian Cardiovascular Society Angina Grade score classified into four classes (I to IV) based on the amount of exertion that triggers the symptoms. The higher the class, the lower the exercise tolerance. |
At 12- and 18-months follow-up
|
|
Patient reported dyspnea score
Time Frame: At 12- and 18-months follow-up
|
Prevalance and impact of dyspnea on patient's daily activities classified by the Medical Research Council Dyspnea Scale. There are 5 grades (0 to 4). The higher the grade, the greater the impact. |
At 12- and 18-months follow-up
|
|
Cost effectiveness analysis between the two treatment groups
Time Frame: At 18 months follow-up
|
Compare healthcare costs and health outcomes of the two treatment arms. Healthcare costs are determined by extracting healthcare utilization data from electronic health records and multiplying these resource-use frequencies by their corresponding standard unit costs in euros. Health outcomes will be evaluated by assessing patient-reported quality of life through the validated questionnaires EuroQol 5 Dimensions (EQ5D). Quality adjusted life years (QALYs) will be derived from the EQ5D outcomes. Costs per QALY will be compared per treatment arm to compare cost-effectiveness. |
At 18 months follow-up
|
|
Patient reported quality of life
Time Frame: At 30 days, 12- and 18-months follow-up
|
Measured by the validated questionnaire EuroQol 5 Dimensions (EQ5D). The EQ5D evaluates a patient's health accross five core dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) giving it a score of 1 (no problems) to 5 (extreme problems). |
At 30 days, 12- and 18-months follow-up
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intention to treat analysis without 30-day adverse event exclusion
Time Frame: At 12- and 18-months follow-up
|
The primary and secondary endpoints will be evaluated in all patients who were initially included at time of ACS diagnosis based on their randomized treatment, i.e., independent of adverse events in the first 30 days after ACS diagnosis and irrespective of received treatment. |
At 12- and 18-months follow-up
|
|
Outcome differences in bleeding events
Time Frame: At 18-months follow-up
|
To compare bleeding events (%) in both treatment arms. |
At 18-months follow-up
|
|
Relation between patients ethnic background (self-reported) and clinical presentation
Time Frame: At 18-months follow-up
|
Does self-defined ethnic background impact the incidence of clinical presentation (STEMI/NSTEMI/unstable angina). For example, is there an association between non-Western European ethnic background and the type of clinical presentation (STEMI/NSTEMI/unstable angina). |
At 18-months follow-up
|
|
Relation between patients highest obtained education level and clinical outcome
Time Frame: At 18-months follow-up
|
Is there a negative correlation between the highest obtained educational level and the incidence of the primary and secondary endpoints (%) |
At 18-months follow-up
|
|
Correlation between Non-enrollers and enrollers
Time Frame: 18 months
|
Clinical outcome (based on primary and secondary endpoints) of patients who were not enrolled vs patients who were enrolled in the study based on data from medical records |
18 months
|
|
Outcome differences diabetes mellitus
Time Frame: At 18 months follow-up
|
Differences in primary and secondary endpoints (%) of diabetic vs non-diabetic participants. |
At 18 months follow-up
|
|
Outcome differences gender
Time Frame: At 18 months follow-up
|
Differences in primary and secondary endpoints (%) of male vs female participants. |
At 18 months follow-up
|
|
Outcome differences elderly
Time Frame: At 18 months follow-up
|
Differences in primary and secondary endpoints (%) of elderly (>= 75 years) vs non-elderly participants. |
At 18 months follow-up
|
|
Outcome differences invasive acute coronary syndrome treatment
Time Frame: At 18 months follow-up
|
Differences in primary and secondary endpoints (%) of participants treated with percutaneous coronary intervention vs non-invasively-treated. |
At 18 months follow-up
|
|
Outcome differences multivessel disease
Time Frame: At 18 months follow-up
|
Differences in primary and secondary endpoints (%) of participants treated with multivessel percutaneous intervention vs non treated with mutlivessel percutaneous intervention. |
At 18 months follow-up
|
|
Outcome differences acute coronary syndrome type
Time Frame: At 18 months follow-up
|
Differences in primary and secondary endpoints (%) of participants with acute myocardial infarction vs unstable angina. |
At 18 months follow-up
|
|
Relation between patients ethnic background (self-reported) and dual antiplatelet use
Time Frame: At 18 months
|
Does self-reported ethnic background impact the incidence of dual antiplatelet use (therapy adherence). For example, does non-Western European ethnic background have an association with higher therapy adherence? This will be measured by self-reported adherence and pharmacist's records of dual antiplatelet therapy pick up. |
At 18 months
|
|
Relation between patients ethnic background (self-reported) and clinical outcome
Time Frame: At 18 months
|
Does ethnic background impact the incidence of the clinical outcome (primary and secondary endpoints). For example, is there an association between non-Western European ethnic background and lower rates of the primary or secondary endpoints. |
At 18 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Clemens von Birgelen, MD, Prof. Dr., Medisch Spectrum Twente
- Study Director: Eline Ploumen, MD, PhD, Medisch Spectrum Twente
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Heart Diseases
- Infarction
- Necrosis
- Myocardial Ischemia
- Ischemia
- Chest Pain
- Angina Pectoris
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- ST Elevation Myocardial Infarction
- Non-ST Elevated Myocardial Infarction
- Myocardial Infarction
- Acute Coronary Syndrome
- Angina, Unstable
Other Study ID Numbers
- MST-TWENTE-V-1394
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.